GigaGen, a subsidiary of Grifols, has commenced a Phase I trial, with the first patient receiving a dose of GIGA-2339 aimed ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback